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Abstract 
Bile formation is a key function of the liver. Disturbance of bile flow may lead to liver disease 
and is called cholestasis. Cholestasis may be inherited such as for example in progressive 
familial intrahepatic cholestasis or acquired, such as for example by drug-mediated inhibition 
of bile salt export from hepatocytes into the canaliculi. The key transport system for exporting 
bile salts into the canaliculi is the bile salt export pump. Inhibition of the bile salt export pump 
by drugs is a well-established cause of drug-induced cholestasis. Investigation of the role of 
the multidrug resistance protein 3, essential for biliary phospholipid secretion, is emerging 
now. This overview summarizes current concepts and methods with an emphasis on in vitro 
model systems for the investigation of drug-induced cholestasis in the general context of 
drug-induced liver injury. 
 
Abbreviations: 
BSEP, bile salt export pump; DILI, drug-induced liver injury; FXR, farnesoid X receptor; 
MDR, multidrug resistance protein; MRP, multidrug resistance-associated protein; NTCP, 
sodium taurocholate-cotransporting polypeptide; OATP, organic anion transporting 
polypeptide; OST, organic solute transporter; PFIC, progressive familial intrahepatic 
cholestasis. 
 
Introduction 
Bile formation is an important function of the liver. Bile assists fat digestion in the intestine 
and mediates the disposal of poorly water soluble endogenous compounds and xenobiotics. 
The major constituents of bile are bile salts (in humans about 67 %), which are taurine or 
glycine conjugates of bile acids and lipids (in humans about 27 %) 1. Canalicular bile is 
produced by hepatocytes, which secrete solutes into the canaliculi followed by water in an 
isosmotic process 2. Hepatocellular bile formation requires the coordinate functioning of 
basolateral solute uptake systems and canalicular export systems for solutes 3. This canalicular 
bile is modified in the bile ducts by cholangiocytes and thereafter leaves the liver 3. Bile flow 
can be separated into bile salt dependent bile flow, which is driven by canalicular bile salt 
secretion and bile salt-independent bile flow, which is driven by canalicular secretion of 
organic anions (other than bile salts) and by bicarbonate secretion into the canaliculus. In 
addition, cholangiocytes contribute significantly to bile salt-independent bile flow by 
secreting bicarbonate into bile 3. In liver disease, bile flow may be impaired to different 
degrees, a condition which was named cholestasis more than 50 years ago 4. 
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Hepatocellular bile salt transport systems 
Bile acids and bile salts reach the liver from the intestine via the portal vein and are taken up 
into hepatocytes across the basolateral membrane, which is exposed to blood plasma. In order 
to efficiently transport bile salts from the portal blood into bile, hepatocytes express several 
uptake and efflux systems in a polarized manner (figure 1). 
 
Under undisturbed physiologic conditions, bile salts are predominantly absorbed by the 
basolateral sodium taurocholate cotransporting polypeptide (NTCP, SLC10A1 [protein name, 
gene name]). As this process is electrogenic, transport may occur against a concentration 
gradient 5,6. Sodium-independent uptake of bile acids is mediated by organic anion 
transporting polypeptides (OATP1B1, SCLO1B1, OATP1B3, SLCO1B3 and OATP2B1, 
SLCO2B1). In vitro experiments have shown that hepatocellular OATPs can mediate transport 
of unconjugated bile acids and conjugated bile salts 7. Once in hepatocytes, bile salts reach by 
a poorly understood mechanism the canalicular membrane. In hepatocytes, imported and 
newly synthesized bile acids are rapidly and efficiently conjugated to taurine or glycine 8,9. 
Export of bile salts across the canalicular membrane occurs against a steep concentration 
gradient and is mediated by a member of the ATP-binding cassette (ABC) transporter 
superfamily. The exclusive transporter for canalicular secretion of primary bile salts is the bile 
salt export pump (BSEP, ABCB11) 5. The release of phosphatidylcholine (PC), the major 
phospholipid in human bile 10,11, into the canaliculus requires at the canalicular membrane the 
activity of the PC translocator MDR3 (ABCB4) and the luminal detergent action of bile salts 
secreted into the canaliculus 12. The P4-ATPase ATP8B1 (ATBP8B1) is an 
aminophospholipid translocator, which assists in maintaining the integrity of the lipid bilayer 
of the canalicular membrane 13. The physiologic role of additional P4-ATPases expressed at 
the canalicular membrane is currently unknown 14. The multidrug resistance-associated 
protein 2 (MRP2, ABCC2) exports bilirubin conjugates as well as other mainly glucuronidated 
metabolites of xenobiotics 15. ABCG2 (ABCG2) mediates the canalicular excretion of a large 
chemical variety of xenobiotics including xenobiotic conjugates 16. This set of transporters is 
complemented by the multidrug resistance protein 1 (MDR1, ABCB1), which mediates 
canalicular export of a wide variety of structurally rather different compounds 17. 
In addition to the above mentioned transport systems, hepatocytes express at the basolateral 
membrane additional efflux systems (figure 1). MRP3 (ABCC3) seems to be a low capacity 
bile salt transporter transporting glycocholate but not taurocholate 18. However, it transports 
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the mono- and bisglucuronide conjugates of bilirubin 19 and drugs and drug metabolites 20. 
MRP4 acts as a glutathione taurocholate cotransporter 21 and transports a wide variety of 
endogenous and exogenous compounds 22. The heterodimeric OSTα/OSTβ is another 
transport system capable of mediating bile salt efflux and other steroid-derived molecules 23. 
Of note, the exact transport mechanism of this transporters remains somewhat elusive, while it 
is established than an association of the two subunits is required for targeting the transporter 
after biosynthesis to the plasma membrane 24. 
 
Cholestasis 
Cholestasis, originally defined as impaired bile flow 4, comprises a variety of clinical entities 
25
 with common clinical features, such as elevated serum alkaline phosphatase and in severe 
cases jaundice. 
 
Cholestasis may be inherited, such as for example in the case of progressive familial 
intrahepatic cholestasis (PFIC), a severe liver disease often requiring liver transplantation at 
young age 26. PFIC1, PFIC2 and PFIC3 are caused by mutations in ATP8B1, ABCB11 and 
ABCB4, respectively 27. The identification of mutations in these genes was instrumental for 
demonstrating the key role of these ATP-dependent systems in canalicular bile formation and 
in bile salt homeostasis in hepatocytes 28,29. As neither BSEP nor MDR3 (and ATP8B1) have 
functional backup systems, any persistent impairment of these transporters will ultimately 
lead to liver disease. Recently, a novel form of PFIC has been described, which is due to 
mutations in the NR1H4 gene encoding the farnesoid X receptor (FXR) 30. FXR is a bile acid 
sensor, which protects hepatocytes from increased bile salt concentrations by repressing the 
biosynthesis of bile acids, repressing the uptake of bile salts and by increasing the canalicular 
export of bile salts via BSEP 31. Four patients with non-functional FXR from two unrelated 
families did not express BSEP and developed severe PFIC leading to death at 5 weeks and 8 
months, respectively or requiring liver transplantation earlier than two years of age 30. This 
highlights the critical role of FXR for BSEP expression in human liver and for the proper bile 
salt homeostasis in hepatocytes. 
 
Alternately, cholestatic liver disease can also be acquired, e.g. as intrahepatic cholestasis of 
pregnancy, inflammation-induced cholestasis (during sepsis), drug-induced cholestasis, 
primary biliary cirrhosis or as primary sclerosing cholangitis 32. While PFICs are rare, 
monogenetic diseases, acquired forms of liver disease are more frequent and are caused by 
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multiple intrinsic and exogenous factors and may include a genetic predisposition, i.e. 
polymorphic variants of susceptibility genes 33,34. The understanding of the molecular 
pathogenesis of acquired cholestatic liver diseases is incomplete and the currently available 
different animal models (e.g. for primary cholangitis) may not complete model such forms of 
liver disease 6,35-38. 
 
Drug-induced cholestatic liver disease is a subtype of drug-induced liver injury (DILI) 39,40. 
Idiosyncratic DILI is difficult to diagnose and is in essence a diagnosis by exclusion 41. The 
incidence of DILI is reported as a wide range of figures 42 and may indeed be underdiagnosed 
43
. DILI can be classified in a hepatocellular pattern, a cholestatic pattern and a mixed pattern 
based on specific changes of serum alkaline phosphatase and aminotransferase levels 39,44. 
The incidence of cholestatic and mixed DILI is not known, but my account for up to 50 % of 
DILI 42,45. 
 
Role of BSEP in drug-induced cholestasis 
As BSEP is the only hepatocellular export system for primary bile salts into the canaliculus, 
interference of drugs and/or their metabolites with BSEP function may lead to drug-induced 
cholestasis. Such a mechanism has been reported for bosentan 46 and is now a well-accepted 
mechanism for drug-induced bland cholestasis 43. BSEP may be inhibited directly from the 
cis-side (cytoplasm) by drugs and/or drug metabolites 47,48. In addition, as exemplified by 
estradiol-17β-glucuronide, BSEP may be inhibited from the trans-side (canaliculus), a process 
which requires secretion of the perpetrator into the canaliculus prior to its inhibitory action 
18,47,48
. Using a vesicular transport assay with BSEP expressed in insect cells 48, over 600 
drugs have been tested for their potential as BSEP inhibitors 4948. Morgan and coworkers 
found a 95 % association of 109 drugs with different forms of DILI after factoring the IC50 
values for BSEP inhibition with drug exposure. This clearly demonstrates the validity and 
predictive potential for the involvement of BSEP in DILI. When in addition the inhibitory 
potential of these drugs against MRP2, MRP3 and MRP4 was taken into account, the 
correlation with different forms of DILI was close to complete 49. 
 
5048,515253
 
In addition to directly or indirectly inhibiting the transport activity of BSEP, drugs may also 
affect the transcriptional regulation of ABCB11 and consequently BSEP expression leading to 
DILI. In a primary human hepatocyte culture system, out of 30 drugs known to inhibit the 
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transport activity of BSEP, five drugs including troglitazone and lopinavir were found to be 
potent repressors of ABCB11 based on mRNA and protein determination 54. In vitro trans-
activation assays showed a concentration-dependent inhibition of FXR activity and hence 
these drugs can be considered as FXR antagonists 54. Following a different approach, a study 
using mechanistic modeling of bile salt homeostasis in the presence of a theoretical BSEP 
inhibitor revealed that the most important unknowns of bile salt homeostasis, based on a 
sensitivity analysis, are the level of BSEP expression, the magnitude of FXR-regulation and 
the intestinal production of the secondary bile acid lithocholic acid 55. With a system 
pharmacology approach in combination with in vitro studies, some non-steroidal anti-
inflammatory drugs were also found to be FXR antagonists 56 These studies suggest a role of 
FXR in DILI, however the relevance/and or importance of FXR in DILI are not yet worked 
out in detail 57. Adding an additional level of regulation (and complexity) to bile salt 
homeostasis, the micro RNA miR-33 has been found to downregulate the mRNAs for mBSEP 
and mATP8B1 in a mouse model 58. In the same model, statins can induce miR-33, which in 
turn leads to a down-regulation of mRNAs coding for mBSEP and mATP8B1. Such a 
mechanism may contribute to statin-induced liver injury. However, it should be noted that the 
statin concentrations used in the above experiments were very high.  
 
It should be kept in mind that not only parent compounds but also drug metabolites can inhibit 
efflux systems, as e.g. demonstrated for bosentan 46 or troglitazone-sulfate and BSEP 50. The 
mechanism of troglitazone-induced DILI is complex and may also involve damage of 
mitochondria by reactive metabolites 48,51. Inhibition of BSEP by troglitazone and 
troglitazone-sulfate leads to an intracellular accumulation of bile salts, which are toxic to 
mitochondria 52. Given the antagonistic effect of troglitazone (and other drugs) on FXR, the 
hepatoprotective response triggered by FXR activation through elevated bile salts 59 may well 
be attenuated. Such a process could further aggravate hepatocyte injury and consequently 
result in severe liver injury. The example of troglitazone shows that the establishment of the 
exact mechanism of DILI requires different and complementary experimental models. Hence, 
using a transport assay with membrane vesicles overexpressing BSEP is just one of several 
tools for investigating the role of BSEP (and other transporters) in cholestatic liver injury 53. 
 
Role of MDR3 in drug-induced cholestasis 
Considering that mutations in ABCB4 coding for MDR3 lead to severe liver disease, it is 
conceivable that inhibition of this ABC-transporter by drugs would also lead to drug-induced 
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acquired liver injury. One can speculate that, similarly to patients with mutations in ABCB4 26, 
serum levels of γ-glutamyl transpeptidase (γGTP) would be elevated in patients with drug-
mediated inhibition of MDR3. Indeed, three patients with DILI receiving itraconazole were 
reported to have DILI with elevated γGTP 60. In an in vitro secretion assay based on 
biosynthetically labeling PC with [14C]choline, 1 µM itraconazole was found to inhibit 
MDR3 activity by about 50 % 60. Using a deuterated choline as PC precursor and primary 
human hepatocytes kept in suspension, an IC50 of 2.1 µM for itraconazole on the inhibition of 
PC efflux from human hepatocytes was observed 61. As canalicular lipid secretion requires the 
interaction of three different ABC transporters 12, a polar LLC-PK1 cell line stably expressing 
BSEP, MDR3 and ABCG5/ABCG8 at the apical membrane and NTCP at the basolateral 
membrane was established 62. Using this cell line for modelling canalicular lipid secretion, 
itraconazole was found to inhibit the secretion of the fluorescent PC derivative 1-palmitoyl-2-
{6-[(7-nitro-2-1,3-bonzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phoshpocholine (C6-
NBD-PC) by 42 % at 10 µM. 
 
Hence, while all three mentioned studies found qualitatively an inhibition of MDR3 by 
itraconazole, there were considerable quantitative differences. All three research groups used 
fundamentally different experimental systems. Yoshikado and coworkers incubated a 
transiently transfected cell line with radioactively labelled choline as a biosynthetic precursor 
for PC and determined the PC efflux in the presence of extracellular 3 mM taurocholate. It is 
interesting to note that taurocholate stimulated PC secretion by 100 % in MDR3 transfected 
cells in comparison to GFP transfected cells, which already displayed a considerable PC 
efflux 60. The latter could indicate that taurocholate impaired the viability of the cells. He and 
coworkers measured the release of a biosynthetically labelled PC from suspended human 
hepatocytes at an unspecified extracellular taurocholate concentration 61. Hepatocytes in 
suspension very likely show no cell polarity with respect to the expression of ABC-
transporters 63, similar to what is observed for freshly thawed hepatocytes suspensions 64. 
Both of the above mentioned studies did also not use an acceptor for the poorly water soluble 
PC besides taurocholate and did not provide information, whether the impact of taurocholate 
on cell viability was checked. In both studies, an interference of itraconazole (and other drugs 
tested) on the biosynthesis of PC cannot entirely be ruled out. Mahdi and coworkers tested the 
impact of itraconazole on MDR3 mediated secretion of the fluorescent PC C6-NBD-PC under 
a basolateral to apical, i.e. transcellular flux of taurocholate, which mimics the physiologic 
situation in hepatocytes and with albumin in the apical compartment as phospholipid acceptor 
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62
. To the best of our knowledge, currently no data on the affinity (Km) of PC or C6-NBD-PC 
to MDR3 are available. However, since the chemical structures of C6-NBD-PC and PC differ, 
also their Km values for MDR3 might differ. This difference may explain the lower potential 
of itraconazole for MDR3 inhibition in the study by Mahdi et al., which observed the 
following rank order for MDR3 inhibition by different azoles: posaconazole > itraconazole > 
ketoconazole, while fluconazole and voriconazole did not inhibit. He et al. observed the 
following rank order for azoles: itraconazole (IC50 2.1 µM) > clotrimazole (IC50 4.6 µM) > 
ketoconazole (IC50 5.6 µM). Using a transcellular taurocholate transport assay in their novel 
cell line, Mahdi et al could demonstrate that itraconazole ~ posaconazole < ketoconazole 
inhibit apical taurocholate secretion by inhibiting BSEP. This rank order parallels published 
IC50 values as BSEP inhibitors for these drugs: 18 µM, 8.1 µM and 3.3 µM, respectively 65. 
 
Impact of expression system on transporter function and inhibition constantsTaking these 
three studies on the inhibition of MDR3 by drugs together, it is evident that the different 
conditions and experimental systems used lead to the quantitatively different findings. Hence, 
for becoming a valuable predictive tool, systems and assays for the assessment of the 
inhibition of MDR3 by drugs will certainly need a standardization. A similar approach is also 
needed for studying the in vitro the interaction of drugs with BSEP. The vmax of BSEP is 
known to be sensitive to membrane cholesterol content 66,67. In addition, it has been 
demonstrated that the cooperativity of MRP2 may change in a substrate-dependent manner 
depending on the cholesterol content of the membrane expression system 67. These examples 
clearly demonstrate a need for standardization of models used for in vitro assessment of 
transporter-related DILI, both with respect to cell system used as well as with respect to 
detailed assay conditions. This necessity can be further illustrated by a study involving 23 
laboratories and a set of 16 inhibitors of MDR1, which yielded a 796-fold maximal range for 
an IC50 value between the involved laboratories 68. Such differences approaching three orders 
of magnitude of variability for kinetic transporter parameters are clearly not useful for any 
predictions and extrapolations from an in vitro to an in vivo situation. The necessary 
standardization of assays in order to make results between different laboratories better 
comparable, e.g. in the area of transport studies, is only at the beginning 69. Importantly, it has 
to be kept in mind that determination of IC50 values for drugs interacting with transporters 
does not provide information on the type of inhibition, which however needs to be known for 
extrapolation to the in vivo situation. Lastly, in vitro results should also be seen in the context 
of the interindividual variability of transport protein expression in healthy human tissues, e.g. 
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human liver. For example, studies using different methodologies showed in what was defined 
as healthy human liver tissue an expression variability for BSEP of 20-fold 70 or 4-fold 71, for 
MDR3 37-fold 70 and 8-fold 71 and for MDR1 22-fold 70, 2-fold 71 or 8-fold 72. Part of these 
differences may be related to differences in liver tissue used and in technical issues, but it is 
conceivable that the interindividual variability of transporter expression is considerable 
between different individuals 73. Such differences in protein expression levels between 
individuals will certainly contribute as a susceptibility factor for drug induced cholestatic liver 
injury and are currently not reflected in the model systems used to assess cholestatic DILI. 
 
Model systems for in vitro investigation of drug-induced cholestasis 
There is clearly a need for using different model systems for assessing the potential for drug-
induced cholestasis of new chemical entities, as different expression systems may lead to 
different quantitative and/or qualitative findings (see above). An overview of examples of 
different experimental systems currently in use for the investigation of the inhibition of e.g. 
BSEP or other efflux transporters is listed in table 1. 
In clinics, diagnosis of drug-induced cholestasis or DILI is very challenging 74. However, a 
careful clinical description of such patients may lead to a detailed hypothesis on the involved 
molecular mechanism of the pathophysiology and as such, patients experiencing DILI should 
be considered a truly "holistic model" of DILI. The precision of the prediction of a 
mechanism from patients may be improved by using evolving new DILI biomarkers for 
plasma 75 and/or urine 76. It is likely that non-invasive imaging of bile flow in patients with 
suspected drug-induced cholestasis may soon be possible 77. Postulated mechanisms can 
subsequently be tested in animal models, such as e.g. isolated perfused rodent livers. Such 
models offer the advantage of representing the entire complexity of a liver including different 
cell types and regulatory mechanism. It should however be kept in mind that drug metabolism 
(e.g. metabolites produced) may differ between rodents and humans. Liver slices and primary 
cultured hepatocytes from human or animal tissues offer a less complex model than the intact 
organ 78. These systems can likely be tested at hepatocellular bile salt concentrations close to 
the in vivo concentration, but suffer from dedifferentiation processes leading to an altered 
expression of transport proteins and drug metabolizing enzymes 78. Finally, a specific 
molecular hypothesis (e.g. BSEP inhibition) can be tested in cell culture systems expressing 
transporters 47 or drug-metabolizing enzymes 79,80. Simultaneous expression of phase I and 
phase II enzymes together with a drug-metabolite transporter has been reported for MRP2 81 
and should also be feasible for BSEP. The investigation of mechanisms of DILI will always 
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be a balance between easily to be used systems and more labor-intense complex holistic 
models 82. 
 
Outlook 
Finally, for successfully predicting (idiosyncratic) DILI, which results from the interplay of 
many different factors 83, "complex" models integrating a multitude (or ideally all) factors and 
different liver cell types would be needed. Development of liver organoids is an emerging 
research area 84,85. An alternate approach, which is currently pursued is represented by so 
called "organ-on-a-chip" models 86-88. Such approaches might be combined or paralleled by in 
silico approaches 89,90. While physiologically based pharmacokinetic (PBPK) modelling 
approaches involve transport and metabolism 91,92 and are combined with wetlab approaches ( 
e.g. drug sulfonation 93), it might be interesting to further evolve such models by taking into 
account a possible specific special arrangement of transporters and drug-metabolizing 
enzymes in hepatocytes. The role of such arrangements is well appreciated in energy 
metabolism and is termed metabolic channeling 94,95. A complementary in silico approach 
constitutes the development of predictive models based on physicochemical descriptors for 
drug-transporter interaction, as recently exemplified for BSEP 96. Even though considerable 
progress has been made in developing test systems for (cholestatic) DILI, in particular for 
elucidating the intrinsic toxicity of a drug, developing models for studying idiosyncratic 
toxicity remains challenging to date 97. It should however also be kept in mind that so far no 
in vitro cell system modelling the liver and capable of generating bile flow is available and it 
is likely that such an achievement will be very challenging. At the clinical level, search of 
susceptibility factors for DILI using genome-wide association studies with DILI 98 has lead 
e.g. to the identification of HLA class I and II alleles as susceptibility factors 99,100 as well as 
to the identification of genes coding for drug-metabolizing enzymes 101. Genetic association 
studies however have not always been successful 102. Induced pluripotent stem cells from 
thoroughly characterized patients suffering from DILI might become an important tool, as 
they carry the (complex) genotypes potentially contributing to DILI in the specific situation 
103,104
. Such cells might well be used as source for use in a classical setup in vitro setup or in 
novel in vitro test systems aimed at predicting DILI. Additionally, and importantly, there is a 
need for novel and more sensitive markers for positively identifying DILI in daily clinical 
practice 105. Finally, novel methods, like imaging are rapidly induced and allow visualization 
of drug transport in humans 106 and are reviewed in 107-110. 
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Table 1 
Model systems used for studying drug-induced cholestasis 
 
level of 
complexity 
endpoint assay system comment Reference 
(examples) 
organism global liver 
function 
liver enzymes 
serum bile salt 
levels 
ICG clearance 
amenable to humans 
(retrospective) and 
animals 
indirect evidence for 
BSEP involvement 
111,112
 
organ global liver 
function 
 
imaging 
methodologies 
 
Imaging is emerging 
and amenable to 
humans 
107,113,114
 
bile formation in situ and 
isolated 
perfused liver 
and 
quantitative data on 
bile flow and bile 
composition. 
secretion of 
metabolites back into 
plasma can be 
determined 
115,116
 
  liver slices 3D-organization 
remains in vitro 
technically 
challenging, limited 
life span 
quantification of 
substances in bile is 
difficult 
117
 
organoid hepatotoxicity spheroids Allows co-culture of 
different liver cell 
types, assessment of 
transport processes 
only indirectly 
possible 
84,85
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cell specific 
functions 
primary 
hepatocytes in 
suspension; 
plated 
hepatocytes 
 
Presence of multiple 
transporters, but state 
of differentiation not 
constant; lack of 
different liver cell 
types 
inter donor variability 
can be advantage or 
disadvantage 
interplay of 
metabolism and 
transport present 
determination of bile 
salt secretion rather 
indirect 
 
78
 
sandwich 
cultured 
hepatocytes 
increased stability of 
differentiation over 
extended culture 
period 
interplay of 
metabolism and 
transport present 
assessment of 
canalicular secretion 
possible 
118
 
subcellular 
level 
specific 
functions 
isolated 
canalicular 
vesicles 
substrate binding site 
experimentally 
accessible 
assays with cytotoxic 
compounds possible 
interplay of 
transporters can be 
assessed 
47
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metabolism is lacking 
individual 
transporter 
direct 
characterization 
 
transfected 
polarized cell 
lines 
 
determination of 
transcellular fluxes 
for measuring efflux 
control for 
endogenous 
transporters necessary 
requires 
cotransfection with 
uptake systems 
cotransfection with 
efflux systems and 
metabolizing 
enzymes possible 
62,81,119,120
 
 
isolated 
membrane 
vesicles from 
transfected 
nonpolar cell 
lines 
substrate binding site 
available 
assays with cytotoxic 
compounds possible 
cotransfection with 
efflux systems 
possible 
membrane lipid 
compositon between 
insect cells and 
mammalian cells 
differs 
47,49,67
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Legend to figure 1: Key transporters in human hepatocytes 
Transporters at canalicular membrane in the center between two schematic hepatocytes are 
exporting substrates into bile. Transporters at the basolateral membrane facing the portal 
blood are importing substances into hepatocytes or exporting substances from hepatocytes 
into the portal blood. NTCP mediates bile salt uptake, OATPs, mediated uptake of bile salts 
and numerous drugs. BSEP exports bile salts into the canaliculus. MRP2 and ABCG2 mediate 
export of negatively charged metabolites of endogenous and exogenous compounds into the 
canaliculus. MDR1 mediates neutral and positively charged xenobiotics into the canaliculus. 
ABCg5/ABCG8, ATP8B1 and MDR3 translocate lipids in the canalicular membrane. MRP3, 
MRP4 and Ostα/β export endogenous and exogenous compounds into the portal blood. 
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Table 1 
Model systems used for studying drug-induced cholestasis 
 
level of 
complexity 
endpoint assay system comment Reference 
(examples) 
organism global liver 
function 
liver enzymes 
serum bile salt 
levels 
ICG clearance 
amenable to humans 
(retrospective) and 
animals 
indirect evidence for 
BSEP involvement 
111,112
 
organ global liver 
function 
 
imaging 
methodologies 
 
Imaging is emerging 
and amenable to 
humans 
107,113,114
 
bile formation in situ and 
isolated 
perfused liver 
and 
quantitative data on 
bile flow and bile 
composition. 
secretion of 
metabolites back into 
plasma can be 
determined 
115,116
 
  liver slices 3D-organization 
remains in vitro 
technically 
challenging, limited 
life span 
quantification of 
substances in bile is 
difficult 
117
 
organoid hepatotoxicity spheroids Allows co-culture of 
different liver cell 
types, assessment of 
transport processes 
only indirectly 
possible 
84,85
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cell specific 
functions 
primary 
hepatocytes in 
suspension; 
plated 
hepatocytes 
 
Presence of multiple 
transporters, but state 
of differentiation not 
constant; lack of 
different liver cell 
types 
inter donor variability 
can be advantage or 
disadvantage 
interplay of 
metabolism and 
transport present 
determination of bile 
salt secretion rather 
indirect 
 
78
 
sandwich 
cultured 
hepatocytes 
increased stability of 
differentiation over 
extended culture 
period 
interplay of 
metabolism and 
transport present 
assessment of 
canalicular secretion 
possible 
118
 
subcellular 
level 
specific 
functions 
isolated 
canalicular 
vesicles 
substrate binding site 
experimentally 
accessible 
assays with cytotoxic 
compounds possible 
interplay of 
transporters can be 
assessed 
47
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metabolism is lacking 
individual 
transporter 
direct 
characterization 
 
transfected 
polarized cell 
lines 
 
determination of 
transcellular fluxes 
for measuring efflux 
control for 
endogenous 
transporters necessary 
requires 
cotransfection with 
uptake systems 
cotransfection with 
efflux systems and 
metabolizing 
enzymes possible 
62,81,119,120
 
 
isolated 
membrane 
vesicles from 
transfected 
nonpolar cell 
lines 
substrate binding site 
available 
assays with cytotoxic 
compounds possible 
cotransfection with 
efflux systems 
possible 
membrane lipid 
compositon between 
insect cells and 
mammalian cells 
differs 
47,49,67
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